Designing peptide receptor agonists and antagonists

Research output: Contribution to journalArticle

281 Citations (Scopus)

Abstract

The most ubiquitous mode for controlling and modulating cellular function, intercellular communication, immune response and information-transduction pathways is through peptide-protein non-covalent interactions. Hormones, neurotransmitters, antigens, cytokines and growth factors represent key classes of such peptide ligands. These ligands might either be processed fragments of larger precursor proteins or surface segments of larger proteins. Athough there are numerous exceptions, such as insulin, oxytocin and calcitonin, most ligands are not used directly as drugs, and often the most useful ligands for therapy would be analogues that act as antagonists of the native ligands. A search for systematic structure-based or ligand-based approaches to designing such ligands has been an important concern. Today, a robust strategy has been developed for the design of peptides as drugs, drug candidates and biological tools. This strategy includes structural, conformational, dynamic and topographical considerations.

Original languageEnglish (US)
Pages (from-to)847-858
Number of pages12
JournalNature Reviews Drug Discovery
Volume1
Issue number11
DOIs
StatePublished - Nov 2002

Fingerprint

Peptide Receptors
Ligands
Peptides
Pharmaceutical Preparations
Protein Precursors
Calcitonin
Oxytocin
Neurotransmitter Agents
Intercellular Signaling Peptides and Proteins
Membrane Proteins
Proteins
Hormones
Insulin
Cytokines
Antigens

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Designing peptide receptor agonists and antagonists. / Hruby, Victor J.

In: Nature Reviews Drug Discovery, Vol. 1, No. 11, 11.2002, p. 847-858.

Research output: Contribution to journalArticle

@article{ff50658428784dafb4ef6f7b91ff5690,
title = "Designing peptide receptor agonists and antagonists",
abstract = "The most ubiquitous mode for controlling and modulating cellular function, intercellular communication, immune response and information-transduction pathways is through peptide-protein non-covalent interactions. Hormones, neurotransmitters, antigens, cytokines and growth factors represent key classes of such peptide ligands. These ligands might either be processed fragments of larger precursor proteins or surface segments of larger proteins. Athough there are numerous exceptions, such as insulin, oxytocin and calcitonin, most ligands are not used directly as drugs, and often the most useful ligands for therapy would be analogues that act as antagonists of the native ligands. A search for systematic structure-based or ligand-based approaches to designing such ligands has been an important concern. Today, a robust strategy has been developed for the design of peptides as drugs, drug candidates and biological tools. This strategy includes structural, conformational, dynamic and topographical considerations.",
author = "Hruby, {Victor J}",
year = "2002",
month = "11",
doi = "10.1038/nrd939",
language = "English (US)",
volume = "1",
pages = "847--858",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Designing peptide receptor agonists and antagonists

AU - Hruby, Victor J

PY - 2002/11

Y1 - 2002/11

N2 - The most ubiquitous mode for controlling and modulating cellular function, intercellular communication, immune response and information-transduction pathways is through peptide-protein non-covalent interactions. Hormones, neurotransmitters, antigens, cytokines and growth factors represent key classes of such peptide ligands. These ligands might either be processed fragments of larger precursor proteins or surface segments of larger proteins. Athough there are numerous exceptions, such as insulin, oxytocin and calcitonin, most ligands are not used directly as drugs, and often the most useful ligands for therapy would be analogues that act as antagonists of the native ligands. A search for systematic structure-based or ligand-based approaches to designing such ligands has been an important concern. Today, a robust strategy has been developed for the design of peptides as drugs, drug candidates and biological tools. This strategy includes structural, conformational, dynamic and topographical considerations.

AB - The most ubiquitous mode for controlling and modulating cellular function, intercellular communication, immune response and information-transduction pathways is through peptide-protein non-covalent interactions. Hormones, neurotransmitters, antigens, cytokines and growth factors represent key classes of such peptide ligands. These ligands might either be processed fragments of larger precursor proteins or surface segments of larger proteins. Athough there are numerous exceptions, such as insulin, oxytocin and calcitonin, most ligands are not used directly as drugs, and often the most useful ligands for therapy would be analogues that act as antagonists of the native ligands. A search for systematic structure-based or ligand-based approaches to designing such ligands has been an important concern. Today, a robust strategy has been developed for the design of peptides as drugs, drug candidates and biological tools. This strategy includes structural, conformational, dynamic and topographical considerations.

UR - http://www.scopus.com/inward/record.url?scp=0036834372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036834372&partnerID=8YFLogxK

U2 - 10.1038/nrd939

DO - 10.1038/nrd939

M3 - Article

C2 - 12415245

AN - SCOPUS:0036834372

VL - 1

SP - 847

EP - 858

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 11

ER -